Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 119,648

Document Document Title
WO/2016/146453A1
The present invention relates to a composition comprising palmitoylethanolamide (PEA) and a vitamin B. The present invention also relates to such a composition for use as a nutraceutical or as a medicament, for use as an analgesic pharma...  
WO/2016/146723A1
The present invention relates to pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of Restless Leg Syndrome (RLS) of a human patient, wherein the human patient prior to tre...  
WO/2016/147659A1
Disclosed are compounds, having the following structure, useful as inhibitors of Phosphodiesterase 1 (PDE1), compositions comprising the compounds, and methods of using the same.  
WO/2016/141756A1
A headache-relieving patch, consisting of a back lining layer, a polymer gel layer and an anti-sticking layer. The anti-sticking layer is located at an upper layer of the polymer gel layer. The back lining layer is located at a lower lay...  
WO/2016/141757A1
A nerve-soothing and eye-relaxing patch and a preparation method therefor. The patch consists of a back lining layer, a polymer gel layer and an anti-sticking layer. The gel layer is prepared from the following raw materials in percentag...  
WO/2016/144704A2
Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, di...  
WO/2016/144441A1
New uses of hypoestoxide, its derivatives and related compounds for treatment and prevention of neurodegenerative diseases (e.g. Parkinsons disease, Alzheimers disease, Huntingtons disease) are described. More specifically, the invention...  
WO/2016/145217A1
The present invention relates to recombinant Glut1 adeno-associated viral vector (rAAV) constructs and related methods for restoring Glut1 expression in Glut1 deficient mammals. In certain embodiments, the rAAV further comprises a chicke...  
WO/2016/142349A1
The present invention relates to the use of creatine kinase or fragments thereof which induce analgesia, and also to the use of pharmaceutical compositions comprising the same, to relief pain.  
WO/2016/142877A1
The present disclosure provides acetate salts of buprenorphine, and its anhydrates, solvates, hydrates, and crystalline forms thereof, where the acetate salts of buprenorphine are essentially free of impurities. The disclosure further pr...  
WO/2016/142310A1
The invention relates to compounds of formula (I) and salts thereof, wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also...  
WO/2016/144647A1
The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and...  
WO/2016/144727A1
A combination of a non-selective, peripheral anticholinergic agent, and a muscarinic receptor agonist, optionally with an acetyl cholinesterase inhibitor, and method of using the same for the treatment of hypocholinergic disorders of the...  
WO/2016/145046A1
This disclosure relates to a method of treating a proteinopathy in a subject, the method comprising administering to the subject an effective amount of a quinuclidine compound. The disclosure also relates to a method of reducing, reversi...  
WO/2016/145219A1
The present disclosure relates to methods and compositions to treat peripheral neuropathies, including demyelinating neuropathies and hereditary neuropathies, e.g., Charcot-Marie-Tooth disease. The invention provides methods and composit...  
WO/2016/144704A3
Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, di...  
WO/2016/141754A1
A nerve-soothing and sleep-aiding patch, consisting of a back lining layer, a polymer gel layer and an anti-sticking layer. The anti-sticking layer is formed by a polyethylene film and is located at an upper layer of the polymer gel laye...  
WO/2016/141758A1
A patch having refreshing and cooling functions and a preparation method therefor. The patch consists of a back lining layer, a gel layer and an anti-sticking layer, which are arranged in sequence. The gel layer comprises the following c...  
WO/2016/145082A1
Tetrahydrothiophene and related heterocyclic analogs and related methods for GABA aminotransferase inactivation.  
WO/2016/141503A1
A stable Apremilast (represented by formula I) crystal form II free of solvates, a preparation method therefor, a pharmaceutical composition and pharmaceutical uses thereof, as well as a mixed crystal of the crystal form II and a crystal...  
WO/2016/143745A1
A composition for promoting energy metabolism, a composition for promoting sympathetic nerve activity, a composition for promoting fat burning, an antiobestic composition or a composition for elevating body temperature, each composition ...  
WO/2016/141499A1
The invention relates to blockers of hemichannels for the treatment of epilepsy. In particular, the invention relates to organic compounds that act as selective inhibitors of hemichannels formed by connexins and which are useful in the t...  
WO/2016/145193A1
The invention features methods and compositions for the treatment of Alzheimer's Disease using lysergic acid diethylamide and pharmaceutically acceptable salts thereof.  
WO/2016/143699A1
Provided are: a compound which is useful as an amyloid oxygenation catalyst that is applicable in vivo and is amyloid-selective, while being applicable not only to Aβ peptides but also to other amyloids; and a prophylactic and therapeut...  
WO/2016/144936A1
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inve...  
WO/2016/144749A1
Transdermal therapeutic system and method of using the same for safely treating hypocholinergic disorders of the central nervous system such as Alzheimer type dementia. The transdermal therapeutic system comprises oxybutynin in combinati...  
WO/2016/144901A1
Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.  
WO/2016/141889A1
Provided are a novel triazolopyrimidine derivative represented by formula II, crystal form and preparation method thereof, and use thereof in the preparation of medicine for resisting coagulation and thrombus, treating or preventing cere...  
WO/2016/139586A1
The present invention is directed to N-desmethylclobazam or any suitable pharmaceutically acceptable thereof useful for the prevention and/or treatment of a chronic pain disorder and related methods and pharmaceutical formulations.  
WO/2016/141219A1
The disclosure herein relates to therapeutically-active compositions and formulations for treating pain, pruritus, irritation, inflammation, and tissue damage due to the irritation and inflammation. Specifically, the disclosure relates t...  
WO/2016/140118A1
A radioactive iodine labeled pyrido[1,2-a]benzoimidazole derivative compound represented by a definite general formula or a salt thereof, or a radioactive medicine comprising the same.  
WO/2016/139635A1
The present invention relates to pharmaceutical compositions for the parenteral administration of melatonin in the form of sterile aqueous solutions, provided with good stability even if devoid of any stabilising excipients and having a ...  
WO/2016/141003A1
The present disclosure relates to novel, safe and efficient processes for the synthesis of Pimavanserin and salts thereof, as well as novel intermediates that can be used in these processes.  
WO/2016/140879A9
Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of rilu...  
WO/2016/139530A2
The present invention relates to a method of treating drug addiction in an individual in need thereof, comprising administering to the individual an effective amount of one or more alkali metals selected from the group consisting of one ...  
WO/2016/140277A1
The present invention provides a peptide comprising any one of (i) an amino acid sequence LSSTQAQQSY (SEQ ID NO: 1), (ii) an amino acid sequence LSSTQAQQSW (SEQ ID NO: 6) and (iii) an amino acid sequence LSSTQAQQSF (SEQ ID NO: 7).  
WO/2016/139351A1
The invention relates to compounds of Formula (I) and their use as selective dipeptidyl peptidase I inhibitors, as well as pharmaceutical compositions comprising said compounds, and methods of treatment involving said compounds.  
WO/2016/139530A3
The present invention relates to a method of treating drug addiction in an individual in need thereof, comprising administering to the individual an effective amount of one or more alkali metals selected from the group consisting of one ...  
WO/2016/139605A1
Carotenoid compositions are described for management, treatment, and/or prevention of stress by reducing cortisol levels and/or improving distribution and/or density of macular pigment and thus improving overall health status. More parti...  
WO/2016/139001A1
The present invention relates to acetylsalicylic acid and derivatives thereof for use in treating symptoms caused by endogenous virus, i.e. depression, schizophrenia, mania or psychosis.  
WO/2016/141188A1
Compounds and compositions that can modulate mitochondrial function in neuronal cells are provided herein, as are methods for using the compounds and compositions to treat or prevent conditions such as Alzheimer´s disease.  
WO/2016/139618A1
A composition comprises green coffee extract and yerba mate extract, and is suitable for mixing or infusing with a.base liquid to obtain an edible drink with an energizing and stimulating effect. A drink is made with such a composition.  
WO/2016/140879A1
Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of rilu...  
WO/2016/141065A1
Methods for treating and preventing pyrexia and other diseases in equines such as horses involving administering an oral pharmaceutical formulation containing metamizole are disclosed.  
WO/2016/138569A1
Provided is a method treating or preventing central neuropathic pain in a subject, which includes administering a 1,2-dithiolane carboxylic acid compound, in particular R-(+)-a-lipoic acid, or a pharmaceutically effective salt or ester t...  
WO/2016/138270A3
Composition and methods for treating brain "plaques" and "tangles" in a patient or an animal wherein the method comprises administration of a therapeutically effective amount of a composition comprising Uncaria tomentosa extract and an o...  
WO/2016/137040A1
The present invention relates to a composition for preventing or treating cerebrophathy or a neurological disorder, containing, as an active ingredient, a composite extract of Polygonum multiflorum, Rehmannia glutinosa, Polygala tenuifol...  
WO/2016/138099A1
The invention relates to methods of treating stress- sensitive psychiatric diseases from trauma in a subject by enhancing ghrelin signaling in the BLA of the subject. The invention also relates to methods of reversing ghrelin resistance.  
WO/2016/136944A1
The purpose of the present invention is to provide a compound that exerts a strong analgesic action against on pain, in particular, against neuropathic pain and/or fibromyalgia syndrome. Provided is a cyclic amine derivative represented ...  
WO/2016/138286A1
The present invention relates to the discovery that IRGM, encoded by a uniquely human gene which confers risk for inflammatory diseases, affects autoophagy through a hitherto unknown mechanism. The present invention shows that IRGM contr...  

Matches 351 - 400 out of 119,648